Readiness
Common causes of delayed TGA applications.
Delays often begin before submission. Unclear product scope, incomplete evidence, inconsistent labelling, or unresolved sponsor responsibilities can slow the pathway and create avoidable follow-up work.
Typical delay points
- Unclear intended purpose or mismatch between claims, IFU, labels, and evidence.
- Incorrect or unsupported device classification.
- Manufacturer evidence that does not cover all products, variants, or manufacturing sites.
- Technical documentation that is difficult to retrieve or not audit-ready.
- Clinical or performance evidence that does not support the claimed use.
- Late decisions about sponsor, distributor, importer, or post-market workflows.
How to reduce risk
Manufacturers should complete a pathway assessment before filing, confirm product scope, review evidence, align labelling, and establish post-market responsibilities. This is especially important for higher-risk devices, IVDs, software, and products with complex variants.
A good submission is not only complete; it is coherent. The intended purpose, evidence, quality system, labelling, and sponsor records should tell the same regulatory story.
How Ocevia helps
Ocevia performs readiness reviews before submission, helping manufacturers identify likely gaps and prioritise fixes. This supports a more controlled application process and a cleaner transition into post-market compliance.